We are aware of a recent Food and Drug Administration (FDA) publication that reports on the association between use of zoledronic acid (Aclasta) and renal impairment. 1 We recognize that […]

We are aware of a recent Food and Drug Administration (FDA) publication that reports on the association between use of zoledronic acid (Aclasta) and renal impairment. 1 We recognize that […]

After rigorous peer review, the Michael Smith Foundation for Health Research (MSFHR) recently awarded the Fraser Health Authority team in British Columbia (BC), a three-year project team grant worth $500,000. […]

The recent study by Bolland and colleagues published in the Lancet Diabetes Endocrinology (Oct 4, 2018) is an updated meta-analysis that evaluated the effects of vitamin D supplementation on fractures, […]

“Patient engagement” is a concept that first appeared around the year 2000 in the United States and is now a growing movement in many countries, including Canada. The core idea […]

Last week, Osteoporosis Canada heard a news story that suggested that there is an increased risk of developing osteonecrosis of bone if you are taking a bisphosphonate medication for osteoporosis. […]

The release of the Osteoporosis Canada 2023 Clinical Practice Guideline will support Canadian healthcare providers in providing the most current evidence-based information for patient centred care to optimise skeletal health […]

Latest News Sandoz receives Health Canada approval for Jubbonti®, first and only denosumab biosimilar for treatment of osteoporosis. May 31, 2024 Health Canada has provided authorization to market Jubbonti® (denosumab […]

This report provides a national overview on diagnosed osteoporosis, related fractures and the osteoporosis care gap among Canadians 40 years and older.  It reports on administrative data from the Canadian […]